Blog

Why is Ozempic covered for diabetes while Wegovy for weight loss is not?

Coverage follows a drug's labeled use and the plan's design, not its ingredient. How Medicare, employer plans and prior authorization work, as of November 2026.

Two injectable medicines can contain the same active ingredient and be treated as two different things by an insurance plan. The pharmacy sees one product that a plan will pay for and another that it will not, and the patient is left asking why the molecule is covered on one prescription and excluded on another.

The short answer is that insurance does not cover a molecule. It covers a product for a use. A drug's coverage depends on what the product is approved and labeled to treat, what the law allows a particular kind of plan to pay for, what the plan's designers chose to include, and what rules the plan applies before it pays. This post takes those layers one at a time, using the semaglutide products as the example, and then gives the facts that were on the record as of November 2026, with a note on where to check for changes. It is an explanation of how coverage works, not medical advice or a recommendation about any drug.

One ingredient, two products

Semaglutide is the active ingredient in several products from the same manufacturer. One brand, Ozempic, is labeled for treating type 2 diabetes, and an oral version, Rybelsus, is also a diabetes product. Another brand, Wegovy, is labeled for chronic weight management in people who meet certain criteria. They differ in dose schedules, in the studies behind their labels, and in the list of conditions each may be used for. The Food and Drug Administration approves a product for specific uses. The word for that is the "indication," and labels change over time as new studies lead to new approvals.

For an insurer or pharmacy benefit manager, those are separate products with separate names, separate codes and separate entries on a drug list. A plan can decide to cover the first and exclude the second without any inconsistency, in the same way that it can cover a drug for epilepsy and exclude the same drug for a cosmetic use.

That is also why "the same drug" is an unreliable guide. The things that determine whether a given prescription is paid are the product, the diagnosis it is prescribed for, and the plan.

Three layers decide coverage

Layer 1: the law for that kind of plan

Not every plan has the same room to choose. For Medicare Part D, Congress wrote into the statute that drugs used for weight loss are not among the drugs a Part D plan may cover. That is the reason Medicare drug plans have long excluded obesity medicines. The exclusion is about the use, so Part D plans can cover a product for a different, medically accepted indication, such as diabetes. Where a product has an additional labeled use that is not weight loss, a Part D plan may be able to cover it for that use. Which uses qualify, for which products, is a matter of the current labels and the current guidance from the Centers for Medicare & Medicaid Services (CMS), and both change.

Other plan types face different rules. ACA marketplace plans must cover ten categories of essential health benefits, including prescription drugs, but each state's benchmark plan defines the specifics, and some plans exclude weight-loss drugs. Medicaid programs are run by states, which choose what drugs to cover within federal rules, so state policy varies. Employer plans have the most discretion, especially self-funded plans, where the employer decides what is covered.

Layer 2: the plan's design

Within the law, each plan chooses what to cover. A plan sets a drug list, called a formulary, and puts drugs on tiers with different cost sharing. A plan can also choose to exclude a whole category of drugs, and many employer plans and some other plans exclude drugs prescribed for weight loss. Cost is the usual reason. Supporters of coverage argue that obesity is a medical condition tied to serious health problems and that treating it can lower other costs. Critics point to the size of the spending, which can fall on every enrollee through premiums, and to uncertainty about long-term use. Both arguments are made in benefits committees and legislatures.

The result is that the same product can be a benefit in one plan and an exclusion in another, within the same state and the same insurer, because employers pick different plan designs.

Layer 3: the rules a plan applies before paying

A plan that does cover a drug for one use usually checks that the prescription is for that use. This is the work of prior authorization, and sometimes of step therapy. Typical checks for a diabetes medicine include the diagnosis, sometimes laboratory results such as a blood-sugar measure, and sometimes proof that a cheaper first-line medicine was tried. Plans differ in what they ask for. The how prior authorization works and what to do when it is denied guide describes the process in general.

This is why a prescription can be approved for one patient and rejected for another with the same drug name. The first has a documented diagnosis the plan covers. The second does not, or the paperwork is incomplete. The pharmacy often sees only a reject code. The medical necessity standard is the plan's test of whether the drug is appropriate for the patient's condition under its rules.

What this means in Medicare, as of November 2026

Medicare is the clearest example, because two federal programs bear on it directly. Everything in this section is as of November 2026.

The Medicare GLP-1 Bridge. CMS launched a program called the Medicare GLP-1 Bridge on July 1, 2026. According to CMS, it offers a $50 monthly copay for weight-management GLP-1 drugs for Medicare Part D enrollees not already covered, and it is available through December 31, 2027. That is a temporary arrangement described by CMS in its announcement, and the details, including who is eligible, how to enroll and what clinical criteria apply, are on CMS's pages. Because the Bridge is a program with a stated end date, whether and how it continues is a question to check with Medicare.gov and your plan, and this post does not speculate about what comes after.

Negotiated prices. The Medicare Drug Price Negotiation Program lets Medicare negotiate prices for selected drugs. The second round of selected drugs, which have negotiated prices that take effect on January 1, 2027, includes Ozempic, Rybelsus and Wegovy on CMS's list, along with other drugs. CMS updated its negotiated-price data file on November 2, 2026. A negotiated price is a price that Medicare and the manufacturer agreed on; it is not the same as what a person pays at the pharmacy, which still depends on the plan's deductible, coinsurance and the Part D out-of-pocket cap. This post does not state the negotiated price, because the current figure is on CMS's site and the amount that reaches an individual depends on the plan. Read more in the medicare drug price negotiation entry.

What does that mean for a person in Part D? Three things, all of which are conditional on the plan and the use:

  1. For diabetes, Part D plans generally cover the diabetes products on their formularies, with the usual tiers and rules, and the 2027 price changes apply to the listed drugs.
  2. For weight loss, the statutory exclusion has been the barrier, and the Bridge is a temporary arrangement for eligible people described above, not a change to the exclusion in the statute.
  3. Some products have additional labeled uses, and a plan may cover them for those uses; ask the plan and prescriber about the current label and the plan's criteria.

The Medicare Part D explained: drug plans, formularies and costs guide covers the basics of Part D, including formularies and costs.

What this means outside Medicare

  • Employer plans. Many exclude weight-loss drugs and cover diabetes drugs, which is exactly the pattern in the title. If your plan excludes the weight-loss product, the my employer plan excludes weight-loss drugs: what are my options? post walks through the steps.
  • Marketplace plans. Drug lists vary by plan and state. Check the exact product on the plan's list before enrolling, using the plan's formulary lookup or by calling the insurer.
  • Medicaid. States decide what to cover, so a person's state program may or may not include weight-management drugs. The state Medicaid agency has the current policy.
  • Plans changing their rules. Drug lists change each plan year and sometimes in the middle of a year, with notice. A drug covered last year can be excluded next year, and the reverse can also happen.

What a patient can do with this

None of this is a way to get around a plan's rules, and it is not advice about which product is right for you. It is a way to ask better questions and avoid a wasted trip.

  • Ask the prescriber what the product is labeled for and what the diagnosis on the prescription will be. The diagnosis should be the one the clinician has actually made.
  • Ask the plan three questions. Is this exact product on the formulary? Is it excluded or does it require prior authorization? What documentation does the plan need?
  • Read the reject message. "Plan exclusion" and "prior authorization required" lead to different next steps; the the pharmacy says my claim was rejected: what each message means post explains the common ones.
  • Do not change a diagnosis or a product to fit coverage. If a plan finds that a claim does not match the medical record, it can deny the claim, and the situation can create problems for the patient and the prescriber. A product that is wrong for you is not made right by a benefit.
  • Appeal what can be appealed. An exclusion written into the plan generally cannot be overturned by a medical-necessity appeal, but a prior authorization denial for a covered use can be, and the how to appeal a denied health insurance claim, step by step guide describes how.

Where to check for updates

This is a fast-moving area, and the facts above are dated November 2026.

  • Medicare.gov and CMS. The Medicare GLP-1 Bridge page, the negotiation program pages and Medicare Plan Finder are the places for current terms, prices and drug lists.
  • Your plan's formulary and plan documents. The formulary and the exclusions list are updated at least yearly. Call member services for the current status.
  • The product's label. A prescriber or pharmacist can say what each product is labeled for today.
  • Your state insurance department or Medicaid agency. For rules that apply to your plan type.
  • A SHIP counselor. SHIP is the State Health Insurance Assistance Program, which gives free Medicare counseling. For the broader picture of coverage for these drugs, see the Does insurance cover GLP-1 drugs like Wegovy and Zepbound? guide.

Key takeaways

  • Plans cover a product for a labeled use, not a molecule, so two products with the same active ingredient can be treated differently.
  • Three layers decide coverage: what the law allows for that kind of plan, what the plan chose to cover, and the prior authorization or step therapy rules it applies.
  • Medicare Part D has long excluded drugs used for weight loss by statute; as of November 2026, CMS runs a temporary Medicare GLP-1 Bridge with a $50 monthly copay through December 31, 2027, and the details are on CMS's pages.
  • Negotiated Medicare prices for the second-round drugs, including semaglutide products, take effect January 1, 2027, but what you pay still depends on your plan.
  • Ask the plan three things (is it covered, does it need approval, what proof is needed), and never fit a diagnosis to a benefit.

Terms used in this guide

Related guides

Latest on this topic